Full Breakdown
Blood Filtration Lowers Soluble Flt-1 in Early Preeclampsia
4/28/2026, 12:30:25 AM
Core Event: Antibody-Embedded Filter Reduces Soluble Flt-1
In a pilot study, researchers at Cedars-Sinai routed the blood of 16 women with early-onset preeclampsia through a filter coated with an antibody that binds soluble Flt-1. The treatment lowered circulating Flt-1 by 17 %, reduced blood pressure and proteinuria, and extended gestation a median of 10 days, with one case lasting 19 days.
Background & Context
Preeclampsia, affecting 3–8 % of pregnancies worldwide, is marked by hypertension, proteinuria, and organ injury. Delivery remains the only definitive cure, and severe cases often require preterm birth, increasing neonatal risk. An FDA-approved test measuring the soluble Flt-1/PlGF ratio can predict disease severity, but it is not widely used in the United States.
Data & Findings
All 16 participants showed a ~17 % drop in soluble Flt-1. Median gestational extension was 10 days; the longest continuation was 19 days, with deliveries at a median of 31 weeks. Reported side effects included false labor, chest discomfort, headaches, and transient liver-enzyme elevations.
Significance
Even a modest delay in delivery can improve fetal growth, weight, and oxygenation, potentially lowering rates of respiratory distress and brain injury associated with extreme prematurity. The approach offers a therapeutic avenue in a field with few advances for decades.
Responses & Controversies
The study was led by nephrologist Ravi Thadhani and obstetrician-researcher S. Ananth Karumanchi at Cedars-Sinai, with input from maternal-fetal specialist Thomas McElrath (Mass General Brigham) and obstetrician Mark Santillan (University of Iowa). Thadhani noted that preeclampsia “doesn’t spare any races or ethnicities” and that fetal growth indicates health. McElrath called the lack of observed harms “encouraging” but said safety data are still needed. Santillan said the small sample “can’t fully address safety concerns” and urged larger, controlled trials. Critics point to the missing control group and ambiguous side-effect attribution, arguing efficacy and safety remain unproven. Both Thadhani and Karumanchi have disclosed financial stakes in firms developing the diagnostic test and related therapies.
Verbatim Quotes
- “It doesn’t spare any races or ethnicities, and while there are some populations that are increased risk, for the most part, it affects really all women around the world,” — Ravi Thadhani, Nephrologist, Cedars-Sinai
- “If they’re growing, that means necessarily they’re healthy and getting the nutrition and oxygen they need,” — Ravi Thadhani, Nephrologist, Cedars-Sinai
- “no harms stood out to either the mother or the fetus,” — Thomas McElrath, Maternal-Fetal Medicine Specialist, Mass General Brigham
- “Because of the study’s small size, it can’t fully address safety concerns, Santillan says.” — Mark Santillan, Obstetrician, University of Iowa
Next Steps
The team plans randomized controlled trials with placebo or standard-care arms to confirm efficacy and monitor long-term maternal-infant outcomes. Positive results could prompt expanded FDA review of the filtration device and inform clinical guidelines for early-onset preeclampsia.
